Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

In the version of the article initially published, in Fig. 3b, the Aleniglipron 120 mg column initially listed LS mean change as “–12.1” and has been updated to read “–12.7,” while in Fig. 4, the data was missing from the bottom-right panel, and all arrows were missing from the “Vomiting” panels. Figures 3 and 4 have now been corrected in the HTML and PDF versions of the article.